menstrual migraine

News

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.

News

AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.